Medpace Inc. (MEDP)

NASDAQ: MEDP · Real-Time Price · USD

304.79

-3.60 (-1.17%)

At close: May 01, 2025, 12:09 PM

-1.17% (1D)

Bid	303.08
Market Cap	8.76B
Revenue (ttm)	2.16B
Net Income (ttm)	416.39M
EPS (ttm)	13.11
PE Ratio (ttm)	23.25
Forward PE	22.52
Analyst	Hold

Ask	306.01
Volume	170,860
Avg. Volume (20D)	510,895
Open	306.15
Previous Close	308.39
Day's Range	293.30 - 310.94
52-Week Range	250.05 - 459.77
Beta	1.46

About MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory...

Sector Healthcare

IPO Date Aug 11, 2016

Employees 5,900

Stock Exchange NASDAQ

Ticker Symbol MEDP

Website https://www.medpace.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for MEDP stock is "Hold." The 12-month stock price forecast is $333, which is an increase of 9.26% from the latest price.

Stock Forecasts

Earnings Surprise

Medpace has released their quartely earnings on Apr 21, 2025:

Revenue of $558.57M exceeds estimates by $31.42M, with 9.30% YoY growth.

EPS of 3.67 exceeds estimates by 0.59, with 14.69% YoY growth.

Why Price Moved

1 week ago

-2.32%

Medpace Holdings shares are trading lower. The com... Unlock content with Pro Subscription

1 week ago

-2.46%

Medpace Holdings shares are trading lower. The company reported Q1 financial results.

News

3 days ago · zacks.com

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two companies is the best option for those l...

1 week ago · seekingalpha.com

Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Off...

1 week ago · zacks.com

Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates

Medpace (MEDP) came out with quarterly earnings of $3.67 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $3.20 per share a year ago.

1 week ago · businesswire.com

Medpace Holdings, Inc. Reports First Quarter 2025 Results

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenu...

2 weeks ago · zacks.com

Analysts Estimate Medpace (MEDP) to Report a Decline in Earnings: What to Look Out for

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

CON vs. MEDP: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Concentra Group (CON) or Medpace (MEDP). But which of these two companies is the best option for those looking...

2 weeks ago · zacks.com

Medpace (MEDP) Surges 9.1%: Is This an Indication of Further Gains?

Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa...

3 weeks ago · zacks.com

Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Medpace (MEDP) closed at $290.10, marking a +1.04% move from the previous day.

3 weeks ago · fool.com

1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist

Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take...

3 weeks ago · seekingalpha.com

Medpace Holdings: It Might Be Time To Buy In

Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties aro...

Load More News